Processing

Please wait...

PATENTSCOPE will be unavailable a few hours for maintenance reason on Saturday 31.10.2020 at 7:00 AM CET
Settings

Settings

Goto Application

1. WO2007145956 - USE OF TGF-β ANTAGONISTS IN TREATMENT OF PARATHYROID-RELATED DISORDERS

Publication Number WO/2007/145956
Publication Date 21.12.2007
International Application No. PCT/US2007/013254
International Filing Date 05.06.2007
IPC
C07K 14/495 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
475Growth factors; Growth regulators
495Transforming growth factor (TGF)
C07K 16/22 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
22against growth factors
CPC
A61P 17/02
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
17Drugs for dermatological disorders
02for treating wounds, ulcers, burns, scars, keloids, or the like
A61P 19/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
19Drugs for skeletal disorders
A61P 21/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
21Drugs for disorders of the muscular or neuromuscular system
A61P 35/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
A61P 35/04
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
04specific for metastasis
A61P 43/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
43Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Applicants
  • NOVARTIS AG [CH]/[CH] (AllExceptUS)
  • NOVARTIS PHARMA GMBH [AT]/[AT] (AT)
  • LU, Chris [US]/[US] (UsOnly)
  • SHEPPARD, Kelly-Ann [US]/[US] (UsOnly)
  • PORTER, Jeffrey [US]/[US] (UsOnly)
  • BAUER, Andreas [DE]/[DE] (UsOnly)
Inventors
  • LU, Chris
  • SHEPPARD, Kelly-Ann
  • PORTER, Jeffrey
  • BAUER, Andreas
Agents
  • PAGLIERANI, Paul, J.
Priority Data
60/810,89005.06.2006US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) USE OF TGF-β ANTAGONISTS IN TREATMENT OF PARATHYROID-RELATED DISORDERS
(FR) UTILISATION D'ANTAGONISTES DU FACTEUR DE CROISSANCE TRANSFORMANT β (TGF-β) DANS LE TRAITEMENT DE TROUBLES ASSOCIÉS À LA PARATHYROÏDE
Abstract
(EN)
The present invention relates to the use of TGF-β antagonists for the treatment, amelioration, and diagnosis of parathyroid-related disorders, e.g., HPT-JT, familial isolated primary hyperparathyroidism (FIPH), and hyperparathyroidism-jaw tumor (HPT-JT) syndrome, as well as its attendant complications. The present invention also relates to the use of modulators of HRPT2 and its related PAF1 complex for the treatment, amelioration, and diagnosis of TGFβ-related disorders, e.g., pulmonary hypertension, cancer, hypertension, fibrosis, wound healing. Assays of the identification of modulators of HRPT2/PAF1 and SMAD/TGFβ are also provided.
(FR)
La présente invention concerne l'utilisation d'antagonistes du TGF-β pour le traitement, l'amélioration, et le diagnostic de troubles associés à la parathyroïde, par exemple, une hyperparathyroïdie associée à une tumeur du maxillaire (HPT-JT), une hyperparathyroïdie primaire isolée de forme familiale (FIPH), et le syndrome de l'hyperparathyroïdie associée à une tumeur du maxillaire (HPT-JT), ainsi que des complications qui en découlent. La présente invention concerne également l'utilisation de modulateurs du gène HRPT2 et de son complexe PAF1 associé pour le traitement, l'amélioration, et le diagnostic de troubles associés au TGFβ, par exemple, l'hypertension pulmonaire, le cancer, l'hypertension, la fibrose, la cicatrisation des plaies. L'invention concerne également des essais relatifs à l'identification de modulateurs du gène HRPT2/PAF1 et du gène SMAD/TGFβ.
Latest bibliographic data on file with the International Bureau